ClinVar Miner

Submissions for variant NM_000310.4(PPT1):c.541G>A (p.Val181Met)

gnomAD frequency: 0.00006  dbSNP: rs148412181
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000169209 SCV000220464 likely pathogenic Neuronal ceroid lipofuscinosis 1 2014-06-27 criteria provided, single submitter literature only
Invitae RCV000169209 SCV000958226 pathogenic Neuronal ceroid lipofuscinosis 1 2024-01-29 criteria provided, single submitter clinical testing This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 181 of the PPT1 protein (p.Val181Met). This variant is present in population databases (rs148412181, gnomAD 0.02%). This missense change has been observed in individuals with neuronal ceroid lipofucinosis (NCL) (PMID: 9664077, 10191107, 10649502, 15464427, 19302939, 22387303, 23374165, 30541466). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 188857). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PPT1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects PPT1 function (PMID: 9664077, 11440996, 28878621). This variant disrupts the p.Val181 amino acid residue in PPT1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 19302939, 21499717). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Equipe Genetique des Anomalies du Developpement, Université de Bourgogne RCV000169209 SCV000965817 pathogenic Neuronal ceroid lipofuscinosis 1 2016-01-04 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000169209 SCV001361117 pathogenic Neuronal ceroid lipofuscinosis 1 2019-03-11 criteria provided, single submitter clinical testing Variant summary: PPT1 c.541G>A (p.Val181Met) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8.7e-05 in 277014 control chromosomes (gnomAD). This frequency is not significantly higher than expected for a pathogenic variant in PPT1 causing Neuronal Ceroid-Lipofuscinosis (Batten Disease) (8.7e-05 vs 0.00073), allowing no conclusion about variant significance. c.541G>A has been reported in the literature in multiple homozygous and compound heterozygous individuals affected with Neuronal Ceroid-Lipofuscinosis (Batten Disease, Das_1998, Santorelli_2013, Poyato_2012). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein enzyme activity. The most pronounced variant effect results in <10% of normal activity (Das_1998, Poyato_2012). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.
Centre for Inherited Metabolic Diseases, Karolinska University Hospital RCV000169209 SCV001571358 pathogenic Neuronal ceroid lipofuscinosis 1 2021-04-12 criteria provided, single submitter clinical testing
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard RCV001723740 SCV001950330 pathogenic Retinitis pigmentosa 2021-04-01 criteria provided, single submitter curation The p.Val181Met variant in PPT1 was identified in an individual with Retinitis pigmentosa, via a collaborative study between the Broad Institute's Center for Mendelian Genomics and the Pierce lab ( Through a review of available evidence we were able to apply the following criteria: PM2, PP3, PM3, PS3, PP1-M, PM1. Based on this evidence we have classified this variant as Pathogenic. If you have any questions about the classification please reach out to the Pierce Lab.
GeneDx RCV002259317 SCV002538723 pathogenic not provided 2022-06-22 criteria provided, single submitter clinical testing Published functional studies demonstrate that V181M results in almost complete loss of wild-type function (Das et al., 2001); Located in the palmitate-binding site and it is hypothesized that the V181M substitution alters the active site pocket (Ohno et al., 2010); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 15464427, 12796825, 12125808, 28878621, 11073228, 11589007, 21990111, 21499717, 24091420, 15965709, 10649502, 31589614, 30541466, 33726816, 23374165, 33849402, 22387303, 11440996, 19793631, 9664077)
Ambry Genetics RCV002345567 SCV002649347 pathogenic Inborn genetic diseases 2019-07-19 criteria provided, single submitter clinical testing The p.V181M pathogenic mutation (also known as c.541G>A), located in coding exon 6 of the PPT1 gene, results from a G to A substitution at nucleotide position 541. The valine at codon 181 is replaced by methionine, an amino acid with highly similar properties. This mutation has been identified in multiple individuals with neuronal ceroid lipofuscinosis, including in the homozygous state in 3 individuals from 2 families (Das AK et al. J. Clin. Invest., 1998 Jul;102:361-70; Waliany S et al. Hum. Mutat., 2000 Feb;15:206-7; Mole SE et al. Hum. Mutat., 1999;14:199-215; Teixeira C et al. J. Neurol., 2003 Jun;250:661-7; P&eacute;rez Poyato MS et al. Gene, 2012 May;499:297-302; Santorelli FM et al. Orphanet J Rare Dis, 2013 Feb;8:19; Sheth J et al. BMC Neurol, 2018 Dec;18:203). Analysis of this mutation in SF9 cells as well as patient derived lymphoblasts showed o detectable palmitoyl-protein thioesterase activity (Das AK et al. Hum. Mol. Genet., 2001 Jun;10:1431-9). Another study suggested abnormal processing of protein containing this mutation (Pezzini F et al. Front Mol Neurosci, 2017 Aug;10:266). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Revvity Omics, Revvity RCV000169209 SCV003826627 pathogenic Neuronal ceroid lipofuscinosis 1 2022-03-14 criteria provided, single submitter clinical testing
Baylor Genetics RCV000169209 SCV004204132 pathogenic Neuronal ceroid lipofuscinosis 1 2023-10-10 criteria provided, single submitter clinical testing
Natera, Inc. RCV000169209 SCV002085986 pathogenic Neuronal ceroid lipofuscinosis 1 2021-06-07 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.